11-112094923-C-A
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 2P and 1B. PM1BP4
The NM_003002.4(SDHD):c.433C>A(p.His145Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000199 in 1,458,918 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_003002.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SDHD | NM_003002.4 | c.433C>A | p.His145Asn | missense_variant | 4/4 | ENST00000375549.8 | NP_002993.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SDHD | ENST00000375549.8 | c.433C>A | p.His145Asn | missense_variant | 4/4 | 1 | NM_003002.4 | ENSP00000364699.3 | ||
ENSG00000255292 | ENST00000532699.1 | n.314+5912C>A | intron_variant | 3 | ENSP00000456434.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000806 AC: 2AN: 248184Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 134896
GnomAD4 exome AF: 0.0000199 AC: 29AN: 1458918Hom.: 0 Cov.: 30 AF XY: 0.0000193 AC XY: 14AN XY: 725798
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Pheochromocytoma;C1847319:Carney-Stratakis syndrome;C1868633:Paragangliomas with sensorineural hearing loss;CN166604:Cowden syndrome 3 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 09, 2023 | This sequence change replaces histidine, which is basic and polar, with asparagine, which is neutral and polar, at codon 145 of the SDHD protein (p.His145Asn). This variant is present in population databases (rs121908984, gnomAD 0.002%). This missense change has been observed in individual(s) with clinical features of Cowden syndrome and a personal and/or family history of head and neck paraganglioma (HNPGL) and/or pheochromocytoma and paranganglioma (PPGL) (PMID: 18678321, 21979946, 29386252). ClinVar contains an entry for this variant (Variation ID: 6918). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SDHD protein function. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on SDHD function (PMID: 18678321). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Mitochondrial complex 2 deficiency, nuclear type 3 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Oct 12, 2023 | - - |
Cowden syndrome 3 Uncertain:1
Uncertain significance, no assertion criteria provided | literature only | OMIM | Aug 01, 2008 | - - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 22, 2022 | The p.H145N variant (also known as c.433C>A), located in coding exon 4 of the SDHD gene, results from a C to A substitution at nucleotide position 433. The histidine at codon 145 is replaced by asparagine, an amino acid with similar properties. In a study of individuals with clinical manifestations suggestive of Cowden Syndrome but who were negative for any pathogenic PTEN gene variants, the SDHD p.H145N variant was identified in a 53 year old female diagnosed with breast carcinoma and renal cell carcinoma and who had no family history of cancer. It was not detected in 700 control samples. Functional studies indicated that the p.H145N variant led to mitochondrial dysfunction and the activation of the MAPK pathway which is usually seen with PTEN dysfunction (Ni Y et al. Am. J. Hum. Genet., 2008 Aug;83:261-8; Ni Y et al. Hum. Mol. Genet., 2012 Jan;21:300-10). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at